REGN5713

REGN5713 is an investigational monoclonal antibody developed by Regeneron Pharmaceuticals. It targets Bet v 1, the major allergen in birch pollen responsible for triggering allergic symptoms in sensitized individuals. REGN5713 is designed to bind and neutralize Bet v 1, thereby reducing allergic responses such as rhinitis and conjunctivitis upon exposure to birch pollen. It is being studied both alone and in combination with other monoclonal antibodies (REGN5714, REGN5715) for the treatment of seasonal allergic rhinitis and conjunctivitis due to birch pollen allergy. The drug acts as an IgE receptor modulator by preventing allergen-induced activation of immune cells involved in allergy[1][2][7].

Other names

bremzalerbartum